Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
:NKTR
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.25Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 8.06%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
Nektar Therapeutics presented a quarter with significant advancements in their REZPEG studies and a strong financial position. However, the ongoing litigation with Lilly and non-cash losses from an equity investment present challenges.Company Guidance
During Nektar Therapeutics' Q1 2025 financial results call, the company provided guidance regarding multiple metrics related to their pipeline and financial health. They highlighted the progress of their immunology pipeline, focusing on the advancement of rezpegaldesleukin (REZPEG) in three Phase 2 studies. The REZOLVE-AD Phase 2b study, with 400 patients, aims to establish safety and efficacy in atopic dermatitis, with results from the 16-week induction period expected in June 2025. They also discussed the REZPEG-AA Phase 2b study in alopecia areata, targeting a December 2025 data release. Financially, the company maintains a strong position with $220.7 million in cash and no debt, projecting a cash runway into Q4 2026. They expect 2025 revenue to be around $40 million, with R&D expenses between $110 million and $120 million. The company is preparing for a quiet period in June ahead of the REZPEG data release.Advancement of REZPEG in Phase 2 Studies
Nektar is advancing rezpegaldesleukin (REZPEG) in three separate Phase 2 studies, including atopic dermatitis, alopecia areata, and Type 1 diabetes. The REZOLVE-AD study for atopic dermatitis has enrolled 400 patients, and top-line results are expected in June 2025.
Strong Financial Position
Nektar ended Q1 2025 with $220.7 million in cash and investments and no debt, projecting a runway into Q4 2026.
Progress in Early-Stage Immunology Pipeline
The IND-enabling studies for NKTR-0165, a TNFR2 agonist antibody, are on track for completion in 2025, with plans to submit an IND filing.
Upcoming Data Presentations
Data from the NKTR-255 oncology program will be presented at the European Hematology Association Congress.
NKTR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NKTR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $0.62 | $0.59 | -4.84% |
Mar 12, 2025 | $0.82 | $0.82 | 0.00% |
Nov 07, 2024 | $1.37 | $1.40 | +2.19% |
Aug 08, 2024 | $1.21 | $1.11 | -8.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Nektar Therapeutics (NKTR) report earnings?
Nektar Therapeutics (NKTR) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Nektar Therapeutics (NKTR) earnings time?
Nektar Therapeutics (NKTR) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NKTR EPS forecast?
NKTR EPS forecast for the fiscal quarter 2025 (Q2) is -0.2.